Mkts

Relmada Therapeutics, Inc.

NASDAQ: RLMD
$3.15+0.05 (+1.61%)
As of Oct 19, 10:15 AM ET

Key statistics

Day range
3.103.22
52-week range
1.808.00
Today
Open3.11
Previous close3.15
Volume1.21M
Valuation
Market cap330.68M
P/E ratio—
EPS (TTM)-0.96
Income & risk
Dividend / yield—
Beta0.57
Avg volume1.62M
Discussion

RLMD News

Stories mentioning RLMD from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue
Cost of Goods Sold
Gross Profit0.000.000.000.000.000.000.000.00
Operating Expenses
Research & Development8,0888,0734,0362,81911,95111,00111,14910,721
Sales General & Admin
Total Operating Expenses19,46220,33410,32710,22118,21819,07523,00918,819
Operating Income (Loss)(19,462)(20,334)(10,327)(10,221)(18,218)(19,075)(23,009)(18,819)
Interest Income960.00388.00247.00321.00440.00655.00856.00963.00
Interest Expense
Other Expense
Pretax Income
Tax Provision
Net Income (Loss)(19,052)(19,869)(10,091)(9,866)(17,559)(18,657)(21,726)(17,768)
Earnings Per Share (Basic)(0.22)(0.50)(0.30)(0.30)(0.58)(0.62)(0.72)(0.59)
Earnings Per Share (Diluted)(0.22)(0.50)(0.30)(0.30)(0.58)(0.62)(0.72)(0.59)
Weighted Average Shares Outstanding (Basic)86,59739,48033,19233,19230,40930,16430,17430,174
Weighted Average Shares Outstanding (Diluted)86,59739,48033,19233,19230,40930,16430,17430,174

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About RLMD

Relmada Therapeutics, Inc. (NASDAQ: RLMD) is a stock listed on the Nasdaq Stock Market under the ticker symbol RLMD. It last traded at $3.15 (Oct 19, 2026, 10:15 AM ET), up 1.6% on the day. That gives Relmada Therapeutics a market capitalisation of $330.7M.

Over the past 52 weeks RLMD has traded between $1.80 and $8.00.

For the quarter ended Mar 31, 2026 it reported a net loss of $19.1M.

Last 4 quarters
Quarter endedRevenueNet income
Mar 31, 2026—-$19.1M
Dec 31, 2025—-$19.9M
Sep 30, 2025—-$10.1M
Jun 30, 2025—-$9.9M

From Relmada Therapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…